Description: GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
Home Page: grail.com
1525 O’Brien Drive
Menlo Park,
CA
94025
United States
Phone:
833-694-2553
Officers
| Name | Title |
|---|---|
| Mr. Robert P. Ragusa | CEO & Director |
| Dr. Joshua J. Ofman M.D., M.S.H.S | President |
| Mr. Aaron Freidin | Chief Financial Officer |
| Mr. Abram Barth J.D., M.P.H. | General Counsel |
| Mr. Rodger Currie | VP and Head of Government Affairs & Alliance Development |
| Sir Harpal S. Kumar M.A., M.B.A., MA, MBA, MEng | President Biopharma Business & Europe |
| Dr. Satnam Alag Ph.D. | Senior VP of Software Engineering & Chief Security Officer |
| Ms. Alice A. Chen | VP of Product & Head of Program Management Organization |
| Mr. Nathan Hunkapiller Ph.D. | Senior VP of Research & Development |
| Mr. Arash Jamshidi Ph.D. | Senior VP of Data Sciences & Scientific Co-Founder |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2698 |
| Price-to-Sales TTM: | 5.9338 |
| IPO Date: | 2024-06-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 1360 |